Inhalers can be tricky devices to manufacture and for the second time in two weeks a drugmaker is having to recall inhalers because the devices may not deliver any drugs. Following last week's recall by AstraZeneca of asthma inhalers in Denmark, Boehringer Ingelheim is recalling in the U.S. tens of thousands of inhalers used to treat chronic obstructive pulmonary disease.
Melbourne, Australia-based Adherium has pulled off a major pharma partnership just ahead of a proposed listing on the Australian Stock Exchange. It expects to list on Aug. 26, raising up to $35 million and at least $20 million. A new deal that the smart inhaler player just disclosed with AstraZeneca can only enhance its public market prospects.
Philips touted a study in the Journal of Clinical Sleep Medicine concluding that the company's portable home ventilator greatly reduced hospital readmissions among COPD patients.
When Boehringer Ingelheim's COPD drug Stiolto Respimat won U.S. approval early last month, the company's head of pharma marketing and sales, Allan Hillgrove, acknowledged that payer arm-twisting happening stateside may make pricing tough. But now, the German drugmaker has nabbed some European approvals that should give the drug a lift.
Respiratory biotech Pulmatrix has completed its nontraditional path to the public markets, closing a merger with upstart Ruthigen to inherit a Nasdaq listing, at the same time banking $10 million and partnering up with generics giant Mylan.
A group of FDA advisers backed GlaxoSmithKline's latest asthma treatment for use in adults but balked at recommending it for adolescents, setting the stage for a likely approval in the fall.
Makers of respiratory drugs have been cutting prices as they vie for prime formulary positioning with payers. Boehringer's Spiriva has already taken a sales hit as a result, but now, the German pharma is hoping new combo med Stiolto can turn things around.
Boehringer Ingelheim picked up FDA approval for a next-generation COPD treatment, looking to contend for a share of the fast-crowding market for combination therapies.
Novartis, working to get a pair of Europe-approved COPD treatments onto the U.S. market, reported some positive Phase III data while awaiting final word from the FDA.
Remote patient monitoring startup Sentrian has partnered with the Scripps Translational Science Institute to study 1,000 chronic obstructive pulmonary disease (COPD) patients. The one-year study will use biosensors to continuously monitor patients and analyze that data to offer alerts for any deterioration. The intention is to intervene before an even becomes acute and requires hospitalization.